Scholar Rock Holding (SRRK) Non-Current Assets (2017 - 2026)
Scholar Rock Holding (SRRK) recorded quarterly Non-Current Assets of $20.0 million in Q1 2026, up 4.42% quarter-over-quarter from $19.1 million in Q4 2025, and down 10.47% on a YoY basis from $22.3 million in Q1 2025.
Scholar Rock Holding (SRRK) Non-Current Assets (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Non-Current Assets history runs 10 years deep, the most recent figure standing at $20.0 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 10.47% year-over-year to $20.0 million; the TTM figure through Mar 2026 stood at $81.0 million (down 18.98% YoY), while the FY2025 annual figure was $19.1 million, down 19.5% from the prior year.
- Non-Current Assets was $20.0 million for Q1 2026 at Scholar Rock Holding, up from $19.1 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $37.4 million in Q1 2022 to a low of $19.1 million in Q4 2025.
- Historically, Non-Current Assets has averaged $25.5 million across 5 years, with a median of $23.8 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets slumped 32.02% in 2023, then climbed 17.92% in 2024.
- A 5-year view of Non-Current Assets shows it stood at $30.1 million in 2022, then declined by 24.23% to $22.8 million in 2023, then rose by 4.01% to $23.8 million in 2024, then slipped by 19.5% to $19.1 million in 2025, then gained by 4.42% to $20.0 million in 2026.
- The last three Non-Current Assets figures came in at $20.0 million (Q1 2026), $19.1 million (Q4 2025), and $21.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - | 19.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.97 Mn |
| Dec 31, 2025 | 19.13 Mn |
| Sep 30, 2025 | 21.01 Mn |
| Jun 30, 2025 | 20.92 Mn |
| Mar 31, 2025 | 22.31 Mn |
| Dec 31, 2024 | 23.76 Mn |
| Sep 30, 2024 | 26.21 Mn |
| Jun 30, 2024 | 27.73 Mn |
| Mar 31, 2024 | 20.35 Mn |
| Dec 31, 2023 | 22.84 Mn |
| Sep 30, 2023 | 22.22 Mn |
| Jun 30, 2023 | 25.09 Mn |
| Mar 31, 2023 | 27.56 Mn |
| Dec 31, 2022 | 30.14 Mn |
| Sep 30, 2022 | 32.69 Mn |
| Jun 30, 2022 | 34.99 Mn |
| Mar 31, 2022 | 37.39 Mn |
| Dec 31, 2021 | 39.13 Mn |
| Sep 30, 2021 | 40.23 Mn |
| Jun 30, 2021 | 41.69 Mn |